Skip to main content
Premium Trial:

Request an Annual Quote

Court Bars Abbott From Selling HCV Genotyping Products That Infringe Innogenetics IP

NEW YORK (GenomeWeb News) — Innogenetics today said that a US District Court in Wisconsin has barred Abbott Laboratories from using or selling its hepatitis C genotyping technology anywhere in the world after an earlier verdict found Abbott to infringe a US patent held by Innogenetics.
Innogenetics sued Abbott Laboratories in 2005 for infringing US Patent No. 5,846,704. In September 2006 a jury awarded Innogenetics $7 million, and last week the judge in the case upheld that award, denied Abbott a new trial on “infringement and validity,” and set the date to consider barring Abbott permanently from selling the infringing products.  
Innogenetics also sued Third Wave Technologies for allegedly infringing the same IP, but Third Wave settled the case under a non-exclusive licensing agreement and optional extension with Innogenetics.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.